kontek brothers
The United Nations Children's Fund (UNICEF) has launched an emergency tender for the procurement of mpox vaccines for the most affected countries in collaboration with the Africa CDC, the Gavi vaccine alliance, the World Health Organization (WHO), the Pan American Health Organization and other partners.
In a joint statement, the organizations indicated that, depending on demand and the production capacity of manufacturers, agreements could be reached for up to 12 million doses by 2025.
Under the emergency tender, UNICEF will establish conditional supply agreements with vaccine manufacturers, allowing the agency to purchase and ship vaccines without delay once countries and partners have secured funding and met demand, readiness and regulatory requirements.
The collaboration will allow for donations of vaccines from existing stockpiles in high-income countries.
According to the statementThe WHO is currently reviewing the information submitted by manufacturers on August 23 and is expected to complete its review for emergency use listing by mid-September.
In August, the WHO declared the ongoing outbreak a global public health emergency after the Africa CDC, the regional health agency, classified it as a continental public health security emergency and requested 10 million doses of mpox vaccines.
WHO Director-General Tedros Adhanom Ghebreyesus has said an international response plan to combat the current mpox outbreak will require about $135 million over the next six months as a new, deadlier strain of the virus spreads globally.
Countries including Sweden and Thailand have already reported cases of mpox attributed to the clade 1b virus type, which has fueled the recent outbreak centered in Africa. Clade 1b is thought to be more transmissible and lethal than the mild clade 2b variant, which caused the previous mpox outbreak in 2022.
Actions related to vaccines
Vaccine developers for mpox include Bavarian Nordic (OTCPK:BVNKF) (OTCPK:BVNRY), Emergent BioSolutions (New York Stock Exchange: EBS) and Chimerix (NASDAQ: CMRX).
Developers of mpox therapy: GeoVax Labs (NASDAQ:GOVX), SIGA Technologies (NASDAQ: FOLLOW) and Tonix Pharmaceuticals (NASDAQ:TNXP).
Monkeypox Test Manufacturers: Co-Diagnostics (NASDAQ: CODX), Roche (OTCQX:RHHBY) (OTCQX:RHHBF), Abbott Laboratories (New York Stock Exchange:ABT), Applied DNA Sciences (NASDAQ: APDN)
